A recently established investment firm based in Asia and backed by a large industrial family enterprise. The firm manages substantial capital and focuses on early-stage opportunities across life sciences and healthcare. The firm typically invests from Seed through Series B and evaluates opportunities globally. In addition to capital investment, the firm is interested in supporting international companies seeking expansion opportunities into the China market.  

The firm’s investment activity is weighted primarily toward therapeutics, while also maintaining interest in diagnostics, medical technology, and AI-enabled healthcare solutions. Within therapeutics, the firm prioritizes highly innovative, next-generation approaches rather than incremental improvements. Areas of interest include advanced drug delivery technologies for mRNA and gene-editing therapies, particularly non-traditional delivery systems and platforms capable of targeting difficult tissues such as the brain. The firm also evaluates extracellular delivery technologies and next-generation cell therapy approaches designed to improve scalability, manufacturability, and cost efficiency. Modalities of interest include TCR-based platforms, NK cell technologies, and macrophage-targeting approaches. The firm is broadly indication-agnostic and is open to technically complex programs addressing major unmet medical needs.  

The firm does not impose strict requirements regarding company structure or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An early-stage venture capital based in the United States focuses on digital health and AI-enabled healthcare technologies designed to shift healthcare from reactive treatment toward prevention, early diagnostics, and long-term disease management. The firm invests across Pre-Seed through Series A stages using both equity and SAFE structures, with typical check sizes ranging from approximately $200K to $2M. Geographically, the firm focuses on health technology companies expanding into the U.S. market, with particular interest in companies operating on the U.S. East Coast and internationally connected healthcare startups. The firm provides hands-on go-to-market support through a broad healthcare network that assists portfolio companies with U.S. commercialization and market-entry strategy.  

The firm is interested in a wide range of digital health and AI-driven healthcare solutions. Core thematic interests include mental health and well-being, women’s health and femtech, chronic disease management, musculoskeletal health, and senior care. The firm also actively evaluates AI-powered diagnostics and clinical decision-support technologies, behavior change and patient engagement platforms, remote patient monitoring solutions with predictive capabilities, prevention and early-detection technologies, and clinically validated digital therapeutics.  

From a company and management team perspective, the firm does not impose strict requirements regarding company structure or leadership composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

 
A large multi-stage venture capital and private equity firm manages substantial assets across multiple strategies. The firm recently established a dedicated life sciences investment vehicle focused on global venture, growth-stage, and co-investment opportunities. The strategy operates in partnership with major international healthcare and investment organizations to support long-term value creation and commercialization.  

The firm invests broadly across life sciences while expanding its focus into digital healthcare and bio-IT convergence. The strongest areas of interest remain within therapeutics, particularly antibody-drug conjugates (ADC), targeted protein degradation (TPD), and cell and gene therapy. Key therapeutic areas include oncology, metabolic disorders, immunology, and neurology. The firm is also actively evaluating opportunities in AI-enabled healthcare, medical data infrastructure, synthetic biology, next-generation diagnostics, and wearable technologies.  

From a company and management team perspective, the firm prioritizes teams with strong scientific and technical expertise. The investment team includes professionals with R&D and clinical development backgrounds who conduct in-depth technical evaluations. Following investment, the firm leverages strategic global partnerships and industry networks to support commercialization, business development, and technology transfer from academic and research institutions. The firm is particularly interested in companies with strong expansion potential or opportunities positioned for strategic or early exit outcomes. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An early-stage investment and development firm based in the United States operates under an evergreen investment structure. The firm manages substantial long-term capital and maintains flexibility in both investment size and transaction structure. Initial investments typically range from approximately $1M to $10M, with additional reserves available for continued support of successful portfolio companies.  

The firm focuses on medical devices and research tools. Within medical devices, the firm prefers technologies pursuing higher-barrier regulatory pathways, including PMA approvals. Within research tools, the firm invests in technologies that enable or enhance the discovery and manufacturing of therapeutics and diagnostics, particularly those with meaningful commercial scalability and strong recurring revenue potential.  

From a company and management team perspective, the firm seeks to invest in small, early-stage companies led by lean but highly capable management and execution teams. The firm primarily focuses on opportunities in the United States while remaining open to select opportunities in Europe. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Anearly-stage venture capital firm based in the United States is focused on backing transformative healthcare technologies. The firm primarily invests at the pre-Seed stage, supporting companies at formation and early product development. The firm deploys capital from a dedicated early-stage fund and partners with both individual and institutional investors aligned with its focus on innovation and long-term value creation. While the firm invests in U.S.-incorporated companies, it actively supports globally distributed teams and engages with founders across multiple regions.  

The firm specializes in health-focused deep technology, with a primary emphasis on neurotechnology and adjacent medical device innovation. The firm invests in companies developing technologies that diagnose, treat, or enhance human health through brain-centered or neurological approaches. Areas of interest include neurotechnology platforms, medical devices, diagnostics, and enabling technologies at the intersection of science, healthcare, and engineering. In addition to its core neurotech focus, the firm also evaluates broader medtech opportunities with the potential to deliver scalable impact across healthcare systems.  

From a company and management team perspective, the firm partners with mission-driven founders who combine technical depth with a patient-centered approach to innovation. The firm prioritizes teams developing differentiated technologies with strong scientific foundations, clear clinical relevance, and the potential for global impact. The firm engages closely with founders from the earliest stages, providing strategic guidance, long-term perspective, and support in building durable, high-impact companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a multi-family office investment and wealth management platform that combines traditional advisory services with direct investment and co-investment opportunities. The firm allocates capital across both direct company investments and third-party funds, providing exposure to high-growth sectors. The firm operates across Europe and the United States and maintains a flexible investment approach spanning multiple asset classes and stages.  

The firm has an active focus on health technology and life sciences, including precision medicine, biotechnology, and select medical technology opportunities. The firm evaluates both companies and funds across early-stage and growth-stage investments, with an emphasis on scientific and clinical innovation that can drive meaningful long-term impact. Areas of interest include personalized healthcare, advanced therapeutic modalities, and technologies that improve diagnosis, treatment, and patient outcomes.  

From a company and management team perspective, the firm partners with teams demonstrating strong domain expertise, execution capability, and strategic clarity. The firm prioritizes opportunities with robust scientific or technical foundations and credible pathways through development, regulatory processes, and commercialization. The firm invests as a collaborative partner, offering capital alongside strategic insight, co-investment flexibility, and access to a broader network of investors and industry relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A healthcare-focused venture capital firm with a team grounded in biomedical training and industry experience manages both local currency and USD-denominated funds and invests across early and growth stages. The firm has an established track record of investing in companies across multiple financing rounds and geographies, including Asia, North America, and Europe. The firm maintains a strong conviction in long-term growth opportunities within the global healthcare sector, particularly in cross-border innovation.  

The firm invests broadly across therapeutics, medical devices, diagnostics, healthcare IT, and medical services. Within therapeutics, the firm has invested across a range of indications such as oncology, infectious diseases, and autoimmune disorders, covering multiple modalities including small molecules, biologics, and gene-based therapies. The firm also evaluates device and imaging technologies, as well as opportunities in bioinformatics, research tools, and adjacent areas such as animal health. Therapeutic investments typically begin at preclinical stages, while device investments are often made prior to commercialization.  

From a company and management team perspective, the firm does not impose strict requirements and remains open to partnering with a wide range of teams and opportunities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.